ResearchMoz

Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019

GlobalData
Published Date » 2012-06-18
No. Of Pages » 65
   
 GlobalData, the industry analysis specialist, has released its new report, Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Hepatitis A Preventive Vaccines market. The report identifies the key trends shaping and driving the global Hepatitis A Preventive Vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hepatitis A Preventive Vaccines sector. This report is built using data and information sourced from proprietary databases,...
Table of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6

2 Hepatitis A Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 8
2.2.1 Historical Vaccination Coverage (2006-2011) 9
2.2.2 Forecast Vaccination Coverage (2011-2019) 9
2.3 Prognosis 10
2.4 Etiology 10
2.5 Pathophysiology 12
2.6 Signs and Symptoms 13
2.7 Diagnosis 14
2.8 Treatment and Management Options 16
2.9 Referral Pathway 18
2.10 GlobalData Pipeline Report Guidance 20

3 Hepatitis A Preventive Vaccines - Market Characterization 21
3.1 Global Hepatitis A Preventive Vaccines Market Size (2006-2011) 21
3.2 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Global 22
3.3 Hepatitis A Preventive Vaccines Market Size (2006-2011) - The US 23
3.4 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - The US 24
3.5 Hepatitis A Preventive Vaccines Market Size (2006-2011) - France 25
3.6 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - France 26
3.7 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Germany 27
3.8 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Germany 28
3.9 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Italy 29
3.10 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Italy 30
3.11 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Spain 31
3.12 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Spain 32
3.13 Hepatitis A Preventive Vaccines Market Size (2006-2011) - The UK 33
3.14 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - The UK 34
3.15 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Japan 35
3.16 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Japan 36
3.17 Drivers and Barriers for the Hepatitis A Preventive Vaccines Market 37
3.17.1 Drivers for the Hepatitis A Preventive Vaccines Market 37
3.17.2 Barriers for the Hepatitis A Preventive Vaccines Market 37
3.18 Opportunity and Unmet Need Analysis 38
3.19 Key Takeaway 39

4 Hepatitis A Preventive Vaccines - Competitive Assessment 40
4.1 Overview 40
4.2 Strategic Competitor Assessment 40
4.3 Product Profiles for the Major Marketed class of Products in the Hepatitis A Market 41
4.3.1 Havrix 41
4.3.2 Vaqta 42
4.3.3 Twinrix 44
4.3.4 Ambirix 45
4.3.5 Avaxim 46
4.3.6 Epaxal 46
4.4 Key Takeaway 47

5 Hepatitis A Preventive Vaccines - Clinical Trials Mapping 48
5.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 48
5.2 Clinical Trials by Phase 49
5.3 Clinical Trials by Trial Status 50
5.4 Prominent Sponsors 51
5.5 Clinical Trials by Overall Sponsors 52
5.6 Top Companies Participating in Hepatitis A Preventive Vaccines Clinical Trials 53

6 Hepatitis A Preventive Vaccines - Strategic Assessment 54
6.1 Key Events Impacting the Future Market 54
6.2 Hepatitis A Preventive Vaccines: Implications for Future Market Competition 55

7 Hepatitis A Preventive Vaccines - Future Players 56
7.1 Introduction 56
7.2 Company Profiles 56
7.2.1 GlaxoSmithKline 56
7.2.2 Merck & Co 56
7.2.3 Crucell 57

8 KOL Insights 58

9 Hepatitis A Preventive Vaccines - Appendix 59

9.1 Market Definitions 59
9.2 Abbreviations 59
9.3 Bibliography 60
9.4 Methodology 61
9.4.1 Coverage 61
9.4.2 Secondary Research 61
9.4.3 Forecasting 62
9.4.4 Primary Research 64
9.4.5 Expert Panel Validation 65
9.5 Contact Us 65
9.6 Disclaimer 65

List of Tables


Table 1: Comparison between Hepatitis A, B and C 7
Table 2: HAV Endemicity by Region 8
Table 3: Vaccination Coverage (In Percentage) 9
Table 4: Vaccination Coverage (In Percentage) 9
Table 5: History and Physical Examination 14
Table 6: Laboratory and Other Studies for Hepatitis A 15
Table 7: Differential Diagnosis of hepatitis A 15
Table 8: Havrix Dosage and Schedule for Vaccination 16
Table 9: Vaqta Dosage and Schedule for Vaccination 16
Table 10: Twinrix Dosage and Schedule for Vaccination 16
Table 11: UK Guidelines For Hepatitis A Vaccination 17
Table 12: Japanese Hepatitis A Vaccine, Dosage and Schedule 17
Table 13: Hepatitis A Preventive Vaccines Market, Global, Revenue ($m), 2006-2011 21
Table 14: Hepatitis A Preventive Vaccines Market, Global, Forecast ($m), 2011-2019 22
Table 15 Hepatitis A Preventive Vaccines Market, The US, Revenue ($m), 2006-2011 23
Table 16: Hepatitis A Preventive Vaccines, The US, Forecast ($m), 2011-2019 24
Table 17: Hepatitis A Preventive Vaccines Market, France, Revenue ($m), 2006-2011 25
Table 18: Hepatitis A Preventive Vaccines, France, Forecast ($m), 2011-2019 26
Table 19: Hepatitis A Preventive Vaccines Market, Germany, Revenue ($m), 2006-2011 27
Table 20: Hepatitis A Preventive Vaccines Market, Germany, Forecast ($m), 2011-2019 28
Table 21: Hepatitis A Preventive Vaccines Market, Italy, Revenue ($m), 2006-2011 29
Table 22: Hepatitis A Preventive Vaccines Market, Italy, Forecast ($m), 2011-2019 30
Table 23: Hepatitis A Preventive Vaccines Market, Spain, Revenue ($m), 2006-2011 31
Table 24: Hepatitis A Preventive Vaccines, Spain, Forecast ($m), 2011-2019 32
Table 25: Hepatitis A Preventive Vaccines Market, The UK, Revenue ($m), 2006-2011 33
Table 26: Hepatitis A Preventive Vaccines Market, The UK, Forecast ($m), 2011-2019 34
Table 27: Hepatitis A Market, Japan, Revenue ($m), 2006-2011 35
Table 28: Hepatitis A Preventive Vaccines Market, Japan, Forecast ($m), 2011-2019 36
Table 29: Hepatitis A Preventive Vaccines - Clinical Trials by Region/ Country, 2012 48
Table 30: Hepatitis A Preventive Vaccines - Clinical Trials by Phase, 2012 49
Table 31: Hepatitis A Preventive Vaccines - Clinical Trials by Status, 2012 50
Table 32: Hepatitis A Preventive Vaccines - Prominent Sponsors, 2012 51
Table 33: Hepatitis A Preventive Vaccines - Overall Sponsors, 2012 52
Table 34: Hepatitis A Preventive Vaccines - Top Companies Participating in Clinical Trials, 2012 53

List of Figures


Figure 1: Prevalence of Hepatitis A Virus by Region 8
Figure 2: Incidence of Hepatitis A, 1980-2009 10
Figure 3: Pathophysiology of Hepatitis A 12
Figure 4 : Symptoms of Hepatitis A infection 13
Figure 5: Referral Pathway for HAV Vaccination 18
Figure 6: KOL Insights, Hepatitis A Preventive Vaccines in the US, Europe and Japan 19
Figure 7: Hepatitis A Preventive Vaccines Market, Global, Revenue ($m), 2006-2011 21
Figure 8: Hepatitis A Preventive Vaccines Market, Global, Forecast ($m), 2011-2019 22
Figure 9 Hepatitis A Preventive Vaccines, The US, Revenue ($m), 2006-2011 23
Figure 10: Hepatitis A Preventive Vaccines, The US, Forecast ($m), 2011-2019 24
Figure 11: Hepatitis A Preventive Vaccines Market, France, Revenue ($m), 2006-2011 25
Figure 12: Hepatitis A Preventive Vaccines, France, Forecast ($m), 2011-2019 26
Figure 13: Hepatitis A Preventive Vaccines Market, Germany, Revenue ($m), 2006-2011 27
Figure 14: Hepatitis A Preventive Vaccines Market, Germany, Forecast ($m), 2011-2019 28
Figure 15: Hepatitis A Preventive Vaccines Market, Italy, Revenue ($m), 2006-2011 29
Figure 16: Hepatitis A Preventive Vaccines Market, Italy, Forecast ($m), 2011-2019 30
Figure 17: Hepatitis A Preventive Vaccines Market, Spain, Revenue ($m), 2006-2011 31
Figure 18: Hepatitis A Preventive Vaccines Market, Spain, Forecast ($m), 2011-2019 32
Figure 19: Hepatitis A Preventive Vaccines Market, The UK, Revenue ($m), 2006-2011 33
Figure 20 : Hepatitis A Preventive Vaccines Market, The UK, Forecast ($m), 2011-2019 34
Figure 21 : Hepatitis A Preventive Vaccines Market, Japan, Revenue ($m), 2006-2011 35
Figure 22: Hepatitis A Preventive Vaccines Market, Japan, Forecast ($m), 2011-2019 36
Figure 23: Opportunity and Unmet Need in the Hepatitis A Preventive Vaccines Market, 2012 38
Figure 24: KOL Insights, Hepatitis A Preventive Vaccines in the US, Europe and Japan 39
Figure 25: Hepatitis A Preventive Vaccines - Strategic Competitor Assessment, 2012 41
Figure 26: KOL Insights, Hepatitis A Preventive Vaccines in the US, Europe and Japan 47
Figure 27: Hepatitis A Preventive Vaccines - Clinical Trials by Country, 2012 48
Figure 28: Hepatitis A Preventive Vaccines - Clinical Trials by Phase, 2012 49
Figure 29: Hepatitis A Preventive Vaccines - Clinical Trials by Status, 2012 50
Figure 30: Hepatitis A Preventive Vaccines - Prominent Sponsors, 2012 51
Figure 31: Hepatitis A Preventive Vaccines - Overall Sponsors, 2012 52
Figure 32: Hepatitis A Preventive Vaccines - Top Companies Participating in Clinical Trials, 2012 53
Figure 33: Hepatitis A Preventive Vaccines Market - Drivers and Restraints 2012 54
Figure 34: Implications for Future Market Competition in Hepatitis A Preventive Vaccines Market, 2012 55
Figure 35: Hepatitis A Preventive Vaccines - Marketed Products by Company, 2012 56
Figure 36: KOL Insights, Hepatitis A Preventive Vaccines, Major Market 58
Figure 37: GlobalData Market Size Estimation 62
Figure 38 : GlobalData Market Forecasting Model 64

Upcoming Reports:

Hog Production And Pork Market - Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth And Forecast, 2013 - 2019
By - Transparency Market Research
Pigs are the species of animals that belong to Suidae family, are generally farmed for the production of meat. Pigs are commonly known as hogs in the U.S. The meat produced from hogs is termed as pork. One can farm pigs in open field by allowing it to wander freely, in restricted field by providing proper food or in special houses in modern countries. In recent years, the pig farming industry has been diversifying from the traditional one in order to produce higher yields of pork. To get good quality and quantity of pork; providing housing facilities, temperature and humidity control, food...
Mobile Data Traffic Market - Global Industry Analysis, Size, Growth, Share And Forecast, 2012 - 2018
By - Transparency Market Research
With the growth in the market penetration of smart phones, the number of mobile phone users is likely to increase. The popularity of social media is also expected to increase and 14 more applications will see growth in the mobile data traffic market. Mobile traffic data was estimated at 3.9 trillion megabytes in 2011 and it is expected to reach 39.9 trillion megabytes in 2016, whereas mobile data revenue was estimated at USD 326.1 billion in 2011 and is expected to reach USD 628.1 billion in 2016. Moreover, mobile traffic is expected to grow tenfold in the coming five years,...
Electrosurgical Devices Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Global electrosurgical devices market is forecasted to grow at an annual growth rate of 5% and reach a market value of USD 1,412.8 million in 2018. This growth is mainly driven by the increasing demand for minimally invasive procedures and technological innovations that are making surgeries safer and least destructive for surrounding tissues. Advancement in technology is helping reduce problems such as collateral damage to tissues, and eschar enhancing the performance of electrosurgery devices. This is   leading to greater adoption of these devices in healthcare industry....

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

New Drug Shows Early Promise against Heart Attacks and Strokes
Sep 1, 2014  
Sanofi and Regeneron Pharmaceuticals have been working on a new experimental drug that aims to lower cholesterol. Early tests have shown that the drug cuts down risks of heart attacks and strokes in clinical trials by half. The test report says that the results are not conclusive as the analysis was performed retrospectively. The study does provide the positive result that...
Western Africa economies hit by Ebola travel ban
Aug 28, 2014  
With over 1,400 people dead due to the fatal Ebola outbreak in African countries, travel services have either banned or limited operations to the western region, severely hitting economies of the area. Budgetary resources are being utilized rapidly and economic growth has dropped by 4% as international projects and trips have been cancelled. Transport companies have cut off the region...
Fonterra Ties Up With Beingmate to Tap into China’s Baby Food Market
Aug 28, 2014  
Fonterra Co-Operative Group Ltd. will partner with Beingmate Group Co, China’s biggest infant formula manufacturer to increase its reach in the Chinese market. The New Zealand-based company makes this move with the intent to grab a bigger market share in China after it suffered many setbacks in the food-safety scandal last year.   This partnership will also help Beingmate...
Chinas Leading Asset-Management Company Aims for IPO
Aug 28, 2014  
China’s biggest asset-management company plans to go public by the end of 2015. Chinese authorities are constantly ramping up their interests towards introducing mixed ownership to state-owned huge companies and call for more private capital investments into the economy. According to the news report, China Huarong Asset Management Co., Ltd. will collaborate with eight investors...
Warren Buffet Helps Burger King with Tim Horton Deal
Aug 27, 2014  
Renowned investor Warren Buffet plans to finance Burger King Worldwide Inc.’s acquisition of Tim Hortons Inc., the Canadian coffee chain. Berkshire Hathaway Inc., Warren Buffet’s firm will invest through preferred shares, it is speculated. Nearly 25% of the deal’s financing would be handled by Berkshire. The precise aim for Warren Buffet’s participation is yet...